As per Intent Market Research, the Genomic Biomarker Market was valued at USD 5.4 billion in 2024-e and will surpass USD 13.5 billion by 2030; growing at a CAGR of 14.1% during 2025 - 2030.
The genomic biomarker market plays a crucial role in advancing personalized medicine and improving disease diagnostics and therapeutic monitoring. Genomic biomarkers, which are genetic indicators of disease presence, progression, or response to treatment, have found widespread applications in oncology, cardiovascular, neurological, and infectious diseases. The market has been growing at a rapid pace due to technological advancements, increased demand for precision medicine, and the rise of early diagnosis practices. As pharmaceutical companies and healthcare providers move toward more individualized treatment strategies, genomic biomarkers are becoming essential tools for enhancing clinical outcomes.
Diagnostic Biomarkers Segment Is Largest Owing To Increased Demand for Early Disease Detection
Among the various types of genomic biomarkers, diagnostic biomarkers currently dominate the market. These biomarkers are critical in identifying the presence of diseases, particularly in the early stages, enabling timely treatment and better patient outcomes. The increasing prevalence of chronic diseases, such as cancer and cardiovascular conditions, is fueling the growth of diagnostic biomarkers. Additionally, advancements in next-generation sequencing (NGS) and PCR-based diagnostics have significantly enhanced the sensitivity and accuracy of these biomarkers. As a result, diagnostic biomarkers are being increasingly incorporated into clinical practice, supporting the global trend toward early diagnosis and preventative care.
Next-Generation Sequencing (NGS) Technology Is Fastest Growing Due To Its Precision and Efficiency
In the technology segment, next-generation sequencing (NGS) is the fastest-growing subsegment, driven by its ability to analyze the entire genome at a fraction of the cost and time required by traditional methods. NGS has revolutionized genomic research, enabling high-throughput sequencing and detailed genomic profiling, which is particularly useful for discovering novel biomarkers and understanding complex diseases like cancer. The increasing adoption of NGS in clinical diagnostics and personalized medicine is expected to propel its growth further, as it allows for precise identification of disease-causing mutations and supports the development of targeted therapies. Moreover, NGS technology is expected to play a vital role in drug development and clinical trials, where genetic information can be used to identify patient populations most likely to respond to treatment.
Cancer Diagnostics Segment Is Largest Owing To Rising Cancer Incidences Worldwide
The cancer diagnostics application segment is the largest in the genomic biomarker market due to the rising incidence of cancer globally. Cancer is one of the most common and life-threatening diseases, and genomic biomarkers are increasingly used for its diagnosis, monitoring, and personalized treatment. Biomarkers like genetic mutations, gene expression profiles, and microRNA profiles are being employed to identify cancer early, determine its type, predict treatment responses, and monitor relapse. As cancer therapies continue to evolve, with an emphasis on personalized and precision medicine, the demand for genomic biomarkers in oncology diagnostics is expected to remain strong, making this the dominant application segment.
Pharmaceutical & Biotechnology Companies Segment Is Largest Owing To Strong Investment in Drug Discovery and Development
Pharmaceutical and biotechnology companies are the largest end-user industry in the genomic biomarker market. These companies leverage genomic biomarkers extensively in drug discovery, clinical trials, and the development of targeted therapies. The rising demand for personalized medicines is driving significant investments in genomic research by pharmaceutical firms. By utilizing biomarkers to identify disease mechanisms, predict patient responses to treatments, and identify potential drug candidates, these companies are able to streamline their R&D processes and improve the efficacy of their therapies. Furthermore, collaboration between biopharmaceutical companies and diagnostic firms to co-develop companion diagnostics is contributing to the strong demand for genomic biomarkers in this sector.
North America Region Is Largest Due To Strong Healthcare Infrastructure and Research Activities
Geographically, North America is the largest market for genomic biomarkers. The region benefits from a well-established healthcare infrastructure, advanced research capabilities, and high adoption rates of advanced diagnostic technologies. The U.S. in particular has become a hub for cutting-edge genomic research, with numerous biotech and pharmaceutical companies, academic institutions, and diagnostic companies involved in biomarker discovery and application. Additionally, government initiatives, such as the U.S. Precision Medicine Initiative and the Human Genome Project, have accelerated the growth of genomic biomarkers in clinical practice. With an increasing number of cancer cases and the rising demand for personalized treatments, the North American market is expected to maintain its dominant position in the global genomic biomarker market.
Competitive Landscape: Leading Companies and Market Outlook
The genomic biomarker market is highly competitive, with several global companies leading the charge in technological innovations, biomarker discovery, and product development. Key players in the market include Thermo Fisher Scientific, Agilent Technologies, Roche Diagnostics, Illumina, and QIAGEN, among others. These companies are engaged in strategic collaborations, mergers, and acquisitions to expand their product portfolios and strengthen their position in the market. Additionally, advancements in diagnostic tools, including NGS-based platforms, and growing investments in R&D are key trends shaping the competitive landscape. As the demand for precision medicine and personalized treatments continues to rise, companies are increasingly focusing on the development of innovative genomic biomarkers that can cater to a wide range of diseases, particularly in oncology. With a focus on accelerating biomarker discovery, companies in this space are expected to drive continued growth in the genomic biomarker market
Recent Developments:
- Thermo Fisher Scientific has recently launched a new genomic testing platform aimed at enhancing cancer biomarker discovery, which integrates both genomic and proteomic data.
- Illumina completed the acquisition of Grail for a multi-billion-dollar deal aimed at accelerating its capabilities in early cancer detection through liquid biopsy technology.
- QIAGEN received regulatory approval from the FDA for its new genomic diagnostic panel designed to identify biomarkers for non-small cell lung cancer.
- Bio-Rad Laboratories launched a next-generation PCR kit focused on oncology biomarkers, improving precision in monitoring genetic mutations in cancer patients.
- Abbott Laboratories has partnered with several research institutions to develop advanced genomic biomarker solutions for personalized treatments in cardiovascular diseases.
List of Leading Companies:
- Thermo Fisher Scientific
- Agilent Technologies
- Roche Diagnostics
- Illumina, Inc.
- Bio-Rad Laboratories
- QIAGEN
- Abbott Laboratories
- PerkinElmer
- GE Healthcare
- Siemens Healthineers
- Merck KGaA
- Becton Dickinson and Company
- Bio-Techne
- Thermo Fisher Scientific
- Pacific Biosciences of California
Report Scope:
Report Features |
Description |
Market Size (2024-e) |
USD 5.4 Billion |
Forecasted Value (2030) |
USD 13.5 Billion |
CAGR (2025 – 2030) |
14.1% |
Base Year for Estimation |
2024-e |
Historic Year |
2023 |
Forecast Period |
2025 – 2030 |
Report Coverage |
Market Forecast, Market Dynamics, Competitive Landscape, Recent Developments |
Segments Covered |
Genomic Biomarker Market By Product Type (Diagnostic Biomarkers, Prognostic Biomarkers, Predictive Biomarkers, Pharmacodynamic Biomarkers), By Technology (Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), Microarray Technology, Mass Spectrometry, Fluorescence In Situ Hybridization (FISH)), By Application (Cancer Diagnostics, Cardiovascular Diseases, Neurological Disorders, Infectious Diseases, Personalized Medicine), By End-User Industry (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Diagnostics Laboratories, Healthcare Providers, Government Agencies) |
Regional Analysis |
North America (US, Canada, Mexico), Europe (Germany, France, UK, Italy, Spain, and Rest of Europe), Asia-Pacific (China, Japan, South Korea, Australia, India, and Rest of Asia-Pacific), Latin America (Brazil, Argentina, and Rest of Latin America), Middle East & Africa (Saudi Arabia, UAE, Rest of Middle East & Africa) |
Major Companies |
Thermo Fisher Scientific, Agilent Technologies, Roche Diagnostics, Illumina, Inc., Bio-Rad Laboratories, QIAGEN, Abbott Laboratories, PerkinElmer, GE Healthcare, Siemens Healthineers, Merck KGaA, Becton Dickinson and Company, Bio-Techne, Thermo Fisher Scientific, Pacific Biosciences of California |
Customization Scope |
Customization for segments, region/country-level will be provided. Moreover, additional customization can be done based on the requirements |
1. Introduction |
1.1. Market Definition |
1.2. Scope of the Study |
1.3. Research Assumptions |
1.4. Study Limitations |
2. Research Methodology |
2.1. Research Approach |
2.1.1. Top-Down Method |
2.1.2. Bottom-Up Method |
2.1.3. Factor Impact Analysis |
2.2. Insights & Data Collection Process |
2.2.1. Secondary Research |
2.2.2. Primary Research |
2.3. Data Mining Process |
2.3.1. Data Analysis |
2.3.2. Data Validation and Revalidation |
2.3.3. Data Triangulation |
3. Executive Summary |
3.1. Major Markets & Segments |
3.2. Highest Growing Regions and Respective Countries |
3.3. Impact of Growth Drivers & Inhibitors |
3.4. Regulatory Overview by Country |
4. Genomic Biomarker Market, by Product Type (Market Size & Forecast: USD Million, 2023 – 2030) |
4.1. Diagnostic Biomarkers |
4.2. Prognostic Biomarkers |
4.3. Predictive Biomarkers |
4.4. Pharmacodynamic Biomarkers |
5. Genomic Biomarker Market, by Technology (Market Size & Forecast: USD Million, 2023 – 2030) |
5.1. Polymerase Chain Reaction (PCR) |
5.2. Next-Generation Sequencing (NGS) |
5.3. Microarray Technology |
5.4. Mass Spectrometry |
5.5. Fluorescence In Situ Hybridization (FISH) |
6. Genomic Biomarker Market, by Application (Market Size & Forecast: USD Million, 2023 – 2030) |
6.1. Cancer Diagnostics |
6.2. Cardiovascular Diseases |
6.3. Neurological Disorders |
6.4. Infectious Diseases |
6.5. Personalized Medicine |
6.6. Others |
7. Genomic Biomarker Market, by End-User Industry (Market Size & Forecast: USD Million, 2023 – 2030) |
7.1. Pharmaceutical & Biotechnology Companies |
7.2. Academic & Research Institutes |
7.3. Diagnostics Laboratories |
7.4. Healthcare Providers |
7.5. Government Agencies |
8. Regional Analysis (Market Size & Forecast: USD Million, 2023 – 2030) |
8.1. Regional Overview |
8.2. North America |
8.2.1. Regional Trends & Growth Drivers |
8.2.2. Barriers & Challenges |
8.2.3. Opportunities |
8.2.4. Factor Impact Analysis |
8.2.5. Technology Trends |
8.2.6. North America Genomic Biomarker Market, by Product Type |
8.2.7. North America Genomic Biomarker Market, by Technology |
8.2.8. North America Genomic Biomarker Market, by Application |
8.2.9. North America Genomic Biomarker Market, by End-User Industry |
8.2.10. By Country |
8.2.10.1. US |
8.2.10.1.1. US Genomic Biomarker Market, by Product Type |
8.2.10.1.2. US Genomic Biomarker Market, by Technology |
8.2.10.1.3. US Genomic Biomarker Market, by Application |
8.2.10.1.4. US Genomic Biomarker Market, by End-User Industry |
8.2.10.2. Canada |
8.2.10.3. Mexico |
*Similar segmentation will be provided for each region and country |
8.3. Europe |
8.4. Asia-Pacific |
8.5. Latin America |
8.6. Middle East & Africa |
9. Competitive Landscape |
9.1. Overview of the Key Players |
9.2. Competitive Ecosystem |
9.2.1. Level of Fragmentation |
9.2.2. Market Consolidation |
9.2.3. Product Innovation |
9.3. Company Share Analysis |
9.4. Company Benchmarking Matrix |
9.4.1. Strategic Overview |
9.4.2. Product Innovations |
9.5. Start-up Ecosystem |
9.6. Strategic Competitive Insights/ Customer Imperatives |
9.7. ESG Matrix/ Sustainability Matrix |
9.8. Manufacturing Network |
9.8.1. Locations |
9.8.2. Supply Chain and Logistics |
9.8.3. Product Flexibility/Customization |
9.8.4. Digital Transformation and Connectivity |
9.8.5. Environmental and Regulatory Compliance |
9.9. Technology Readiness Level Matrix |
9.10. Technology Maturity Curve |
9.11. Buying Criteria |
10. Company Profiles |
10.1. Thermo Fisher Scientific |
10.1.1. Company Overview |
10.1.2. Company Financials |
10.1.3. Product/Service Portfolio |
10.1.4. Recent Developments |
10.1.5. IMR Analysis |
*Similar information will be provided for other companies |
10.2. Agilent Technologies |
10.3. Roche Diagnostics |
10.4. Illumina, Inc. |
10.5. Bio-Rad Laboratories |
10.6. QIAGEN |
10.7. Abbott Laboratories |
10.8. PerkinElmer |
10.9. GE Healthcare |
10.10. Siemens Healthineers |
10.11. Merck KGaA |
10.12. Becton Dickinson and Company |
10.13. Bio-Techne |
10.14. Thermo Fisher Scientific |
10.15. Pacific Biosciences of California |
11. Appendix |
A comprehensive market research approach was employed to gather and analyze data on the Genomic Biomarker Market. In the process, the analysis was also done to analyze the parent market and relevant adjacencies to measure the impact of them on the Genomic Biomarker Market. The research methodology encompassed both secondary and primary research techniques, ensuring the accuracy and credibility of the findings.
Secondary Research
Secondary research involved a thorough review of pertinent industry reports, journals, articles, and publications. Additionally, annual reports, press releases, and investor presentations of industry players were scrutinized to gain insights into their market positioning and strategies.
Primary Research
Primary research involved conducting in-depth interviews with industry experts, stakeholders, and market participants across the E-Waste Management ecosystem. The primary research objectives included:
- Validating findings and assumptions derived from secondary research
- Gathering qualitative and quantitative data on market trends, drivers, and challenges
- Understanding the demand-side dynamics, encompassing end-users, component manufacturers, facility providers, and service providers
- Assessing the supply-side landscape, including technological advancements and recent developments
Market Size Assessment
A combination of top-down and bottom-up approaches was utilized to analyze the overall size of the Genomic Biomarker Market. These methods were also employed to assess the size of various subsegments within the market. The market size assessment methodology encompassed the following steps:
- Identification of key industry players and relevant revenues through extensive secondary research
- Determination of the industry's supply chain and market size, in terms of value, through primary and secondary research processes
- Calculation of percentage shares, splits, and breakdowns using secondary sources and verification through primary sources
Data Triangulation
To ensure the accuracy and reliability of the market size, data triangulation was implemented. This involved cross-referencing data from various sources, including demand and supply side factors, market trends, and expert opinions. Additionally, top-down and bottom-up approaches were employed to validate the market size assessment.
NA